News | Peripheral Artery Disease (PAD) | January 25, 2019

Lumee Oxygen Platform Measures Treatment Response in Critical Limb Ischemia

Data reveal injectable monitor measures tissue oxygen level changes in response to standard-of-care procedures, showing potential to help monitor disease progression and guide clinical management for peripheral artery disease

Lumee Oxygen Platform Measures Treatment Response in Critical Limb Ischemia

January 25, 2019 — Profusa announced promising clinical data from two studies evaluating the company's Lumee Oxygen Platform, an injectable tissue-integrated biosensor and an intelligent data platform intended for continuous, real-time monitoring of tissue oxygen levels. The data, presented at the Leipzig Interventional Course (LINC), Jan. 22-25 in Leipzig, Germany, indicate the Lumee platform measures tissue oxygen level changes in both healthy volunteers and patients with critical limb ischemia (CLI).

The device received CE Mark in October 2016 for continuous monitoring of tissue oxygen and is CE Marked for sale in the EU for monitoring tissue-oxygen perfusion as a general indication. In the U.S., it is limited by federal law to investigational use.

Peter Schneider, M.D., vascular surgeon and clinical researcher in limb salvage vascular procedures from Honolulu, Hawaii, presented findings from a healthy volunteer feasibility study. The study evaluated the performance of the Lumee Oxygen Platform in vivo to monitor changes in interstitial tissue oxygen compared to transcutaneous oximetry (tcpO2), demonstrating that the Lumee platform detected changes in tissue oxygen levels.

"Measurements of regional tissue oxygen serve as a proxy to monitor local perfusion and have the potential to guide crucial therapeutic decisions in multiple clinical disciplines for peripheral artery disease, or PAD, and wound management, that are now made on the basis of clinical judgement and experience alone without guidance," said Schneider. "These findings presented at LINC show promise that the Lumee Oxygen Platform can become a valuable tool for clinicians when they need to assess perfusion."

In the study, after the Lumee biosensor was injected in the forearm of seven healthy volunteers, vascular occlusion tests were performed on the arms of enrolled volunteers. Simultaneous measurements of oxygen were recorded using both the Lumee platform and tcpO2, (a commonly used noninvasive technique that measures the oxygen level of tissue below the skin), with repeated tests occurring one to 10 weeks after biosensor injection. Results revealed that the Lumee platform and tcpO2 were highly correlated, with both technologies showing a statistically significant decrease in oxygen levels during occlusion (p<0.001 for each device). Data also revealed the Lumee platform detected faster rates of oxygen change during both the occlusion and recovery phases (p<0.001, Wilcoxon signed-rank test) and detected reactive hyperemia in a higher percentage of tests (38 percent versus 4 percent occlusion tests).

Marianne Brodmann, M.D., interim head of the clinical division of angiology, department of internal medicine at Medical University in Graz, Austria presented findings from an interim analysis of the first 30 patients enrolled in the Oxygen Monitoring Near Ischemic Areas Study (OMNIA). The findings demonstrate that in patients with critical limb ischemia (CLI), tissue oxygen level increases measured with the Lumee platform during revascularization were positively correlated with changes compared to toe brachial index (TBI), a common vascular test used to measure arterial insufficiency. Tissue oxygen levels were also significantly higher in patients who showed wound healing as compared to patients that did not.  

"We are pleased to see that continuous monitoring of extravascular tissue oxygen using the Lumee Oxygen Platform showed a positive correlation to TBI, demonstrating that this technology could be useful to help guide clinical choices during CLI management," said Brodmann. "These data also validate previous research that showed increases in oxygen during revascularization may be a sensitive indicator of wound healing following the procedure."

The OMNIA Study is an ongoing multicenter trial evaluating use cases of the Lumee Oxygen Platform. Preliminary analysis assesses the relationship between oxygen levels, traditional hemodynamics and wound healing in the affected limbs of patients with CLI before, during and one day after revascularization using the Lumee platform. Follow-up visits are conducted around 30, 90, 180 and 365 days. Enrolled patients received four injected Lumee biosensors — three in the foot and one as a reference sensor in the arm.

For more information: www.profusa.com

 

Related Content

Evolutionary Gene Loss May Help Explain Human Predisposition to Heart Attacks
News | Cardiac Diagnostics | July 29, 2019
The loss of a single gene two to three million years ago in our ancestors may have resulted in a heightened risk of...
U.S. Soldiers Have Worse Heart Health Than Civilians
News | Cardiac Diagnostics | June 06, 2019
Active duty Army personnel have worse cardiovascular health compared to people of similar ages in the civilian...
Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
AHA Statement Warns Hookah Smoking May Harm the Heart
News | Cardiac Diagnostics | March 08, 2019
Smoking tobacco in waterpipes, more commonly known as hookahs, results in inhaling toxic chemicals, often at levels...
PTSD Alone Does Not Increase Heart Disease Risk in Veterans
News | Cardiac Diagnostics | February 20, 2019
February 20, 2019 — Post-traumatic stress disorder (PTSD) by itself does not explain the...
Overlay Init